Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies

被引:0
|
作者
Olejarz, Wioletta [1 ,2 ]
Sadowski, Karol [1 ,2 ,3 ]
Szulczyk, Daniel [4 ]
Basak, Grzegorz [3 ]
机构
[1] Med Univ Warsaw, Fac Pharm, Dept Biochem & Pharmacogen, PL-02097 Warsaw, Poland
[2] Med Univ Warsaw, Ctr Preclin Res, PL-02097 Warsaw, Poland
[3] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
[4] Med Univ Warsaw, Chair & Dept Biochem, PL-02097 Warsaw, Poland
关键词
CAR-T; EVs; immunotherapy; biomarkers; hematological malignancies; checkpoint inhibitors; TME; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; EPSTEIN-BARR-VIRUS; CELL-FREE DNA; CIRCULATING TUMOR DNA; NON-HODGKIN-LYMPHOMA; INHIBITORY RECEPTORS; IMMUNE MICROENVIRONMENT; GENE REARRANGEMENTS; MULTIPLE-MYELOMA;
D O I
10.3390/ijms25147743
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food and Drug Administration (FDA). Significant barriers to the effectiveness of CAR-T therapy include cytokine release syndrome (CRS), neurotoxicity in the case of Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), antigen escape, modest antitumor activity, restricted trafficking, limited persistence, the immunosuppressive microenvironment, and senescence and exhaustion of CAR-Ts. Furthermore, cancer drug resistance remains a major problem in clinical practice. CAR-T therapy, in combination with checkpoint blockades and bispecific T-cell engagers (BiTEs) or other drugs, appears to be an appealing anticancer strategy. Many of these agents have shown impressive results, combining efficacy with tolerability. Biomarkers like extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor (ctDNA) and miRNAs may play an important role in toxicity, relapse assessment, and efficacy prediction, and can be implicated in clinical applications of CAR-T therapy and in establishing safe and efficacious personalized medicine. However, further research is required to fully comprehend the particular side effects of immunomodulation, to ascertain the best order and combination of this medication with conventional chemotherapy and targeted therapies, and to find reliable predictive biomarkers.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy
    Li, Yingying
    Wu, Jianghua
    Luo, Lili
    Hu, Yu
    Mei, Heng
    BLOOD, 2023, 142
  • [32] PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
    Singh, Shashi B.
    Bhandari, Sadikshya
    Siwakoti, Shisir
    Kumar, Manoj
    Singh, Rajshree
    Bhusal, Subarna
    Sharma, Karuna
    Bhandari, Samikshya
    Khanal, Kishor
    MOLECULAR IMAGING, 2024, 23
  • [33] Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
    Kilgour, Marisa K.
    Bastin, Donald J.
    Lee, Seung-Hwan
    Ardolino, Michele
    McComb, Scott
    Visram, Alissa
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Erratum to: CAR T Cell Therapy for Hematological Malignancies
    Xin Yang
    Gao-xiang Wang
    Jian-feng Zhou
    Current Medical Science, 2021, 41 : 187 - 187
  • [35] CAR T-Cell Therapy in Hematological Malignancies
    Haslauer, Theresa
    Greil, Richard
    Zaborsky, Nadja
    Geisberger, Roland
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [36] CAR-T Cell Therapy for T-Cell Malignancies
    Testa, Ugo
    Chiusolo, Patrizia
    Pelosi, Elvira
    Castelli, Germana
    Leone, Giuseppe
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [37] Secondary Malignancies after CAR-T Cell Therapy
    Rudek, Loreen Sophie
    Alakus, Hakan
    ONKOLOGIE, 2024, : 110 - 111
  • [38] CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
    Tan, Jing Yuan
    Low, Muhammed Haiqal
    Chen, Yunxin
    Lim, Francesca Lorraine Wei Inng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [39] Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
    Song, Wenting
    Zhang, Mingzhi
    CLINICAL IMMUNOLOGY, 2020, 214
  • [40] Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances
    Cheloni, Giulia
    Capelletti, Marzia
    Torres, Daniela
    Bindal, Poorva
    Liegel, Jessica J.
    Stroopinsky, Dina
    Bisharat, Lina
    Rahimian, Maryam
    Yoo, Seo Yeon
    Hauser, Joshua
    Koshy, Anita G.
    Dufort, Kenel
    Clohessy, John G.
    Kufe, Donald
    Themeli, Maria
    Rosenblatt, Jacalyn
    Sadelain, Michel
    Avigan, David
    BLOOD, 2021, 138